BIOATLA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
BIOATLA, INC. (BCAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 95.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-31
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 86.90%, a 12.42% increase year-over-year.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 77.30%, a 1.18% increase year-over-year.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 76.40%, a 0.00% change year-over-year.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-03-31 was 76.40%.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 95.30%, a 7.44% increase from fiscal 2024.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 88.70%, a 1022.78% increase from fiscal 2023.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 7.90%, a 89.45% decline from fiscal 2022.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 74.90%, a 0.27% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | 95.30% 10-K · filed 2026-03-31 | ||||||
| 2024-12-31 | 88.70% 10-K · filed 2026-03-31 | 8.70% 10-K · filed 2025-03-28 | |||||
| 2024-09-30 | 88.70% 10-Q · filed 2024-11-07 | ||||||
| 2024-06-30 | 88.10% 10-Q · filed 2024-08-08 | ||||||
| 2024-03-31 | 86.90% 10-Q · filed 2024-05-14 | ||||||
| 2023-12-31 | 7.90% 10-K · filed 2025-03-28 | 77.90% 10-K · filed 2024-03-26 | |||||
| 2023-09-30 | 77.90% 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | 77.40% 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 77.30% 10-Q · filed 2024-05-14 | ||||||
| 2022-12-31 | 74.90% 10-K · filed 2024-03-26 | ||||||
| 2022-09-30 | 74.80% 10-Q · filed 2023-11-07 | ||||||
| 2022-06-30 | 74.80% 10-Q · filed 2023-08-01 | ||||||
| 2022-03-31 | 76.40% 10-Q · filed 2023-05-11 | 74.60% 10-Q · filed 2022-05-05 | |||||
| 2021-12-31 | 74.70% 10-K · filed 2023-03-23 | ||||||
| 2021-09-30 | 74.70% 10-Q · filed 2022-11-04 | ||||||
| 2021-06-30 | 74.80% 10-Q · filed 2022-08-09 | 74.76% 10-Q · filed 2021-08-13 | |||||
| 2021-03-31 | 76.40% 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | 74.50% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |